PTGX - プロタゴニスト・セラピュ―ティクス (Protagonist Therapeutics Inc.)

PTGXのニュース

   Protagonist Therapeutics Reports Granting of Inducement Award  2021/06/30 20:27:00 Business Insider Markets
NEWARK, Calif., June 30, 2021 /PRNewswire/ -- Protagonist Therapeutics, Inc. (Nasdaq:PTGX) today reported that on June 30, 2021, it issued an inducement award to Patrick Smith, the Company''s recently hired Vice
   Protagonist Therapeutics closes $132M capital raise  2021/06/18 20:13:32 Seeking Alpha
   Protagonist Therapeutics Secures $115M Via Equity Raise  2021/06/16 10:53:35 Benzinga
Protagonist Therapeutics Inc (NASDAQ: PTGX ) priced its previously announced underwritten public offering of around 3 million common shares to raise gross proceeds of approximately $115 million. The offering was upsized from $100 million announced earlier . The offer price of $37.75/share represents Full story available on Benzinga.com
   Protagonist Therapeutics secures $115M capital via equity raise  2021/06/16 03:44:00 Seeking Alpha
   Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), AbbVie (ABBV) and Protagonist Therapeutics (PTGX)  2021/06/15 05:55:39 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Siemens Healthineers AG (SEMHF), AbbVie The post Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), AbbVie (ABBV) and Protagonist Therapeutics (PTGX) appeared first on Smarter Analyst .
   Protagonist Therapeutics closes $132M capital raise  2021/06/18 20:13:32 Seeking Alpha
   Protagonist Therapeutics Secures $115M Via Equity Raise  2021/06/16 10:53:35 Benzinga
Protagonist Therapeutics Inc (NASDAQ: PTGX ) priced its previously announced underwritten public offering of around 3 million common shares to raise gross proceeds of approximately $115 million. The offering was upsized from $100 million announced earlier . The offer price of $37.75/share represents Full story available on Benzinga.com
   Protagonist Therapeutics secures $115M capital via equity raise  2021/06/16 03:44:00 Seeking Alpha
   Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), AbbVie (ABBV) and Protagonist Therapeutics (PTGX)  2021/06/15 05:55:39 Smarter Analyst
Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Siemens Healthineers AG (SEMHF), AbbVie The post Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), AbbVie (ABBV) and Protagonist Therapeutics (PTGX) appeared first on Smarter Analyst .
   Protagonist Therapeutics slumps 7.5% on raising $100M via public offering  2021/06/14 21:28:56 Seeking Alpha
   Protagonist Therapeutics Inc Shares Climb 2.6% Past Previous 52-Week High - Market Mover  2021/06/07 22:30:00 Kwhen Finance
Protagonist Therapeutics Inc (PTGX) shares closed 2.6% higher than its previous 52 week high, giving the company a market cap of $1B. The stock is currently up 76.2% year-to-date, up 121.3% over the past 12 months, and up 203.6% over the past five years. This week, the Dow Jones Industrial Average rose 0.3%, and the S&P 500 rose 0.5%. Trading Activity Trading volume this week was 60.2% higher than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 1.2. Technical Indicators The Relative Strength Index (RSI) on the stock was above 70, indicating it may be overbought.MACD, a trend-following momentum indicator, indicates an upward trend.The stock closed below its Bollinger band, indicating it may be oversold. Market Comparative Performance The company's share price is the same as the S&P 500 Index , beats it on a 1-year basis, and beats it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , beats it on a 1-year basis, and beats it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , beats it on a 1-year basis, and beats it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date beats the peer average by -407.6% The company's stock price performance over the past 12 months beats the peer average by -886.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Protagonist Therapeutics to Host Investor Conference Call and Webcast to Discuss Updated Phase 2 Rusfertide Results in Polycythemia Vera as Presented at EHA 2021  2021/06/07 00:00:00 BioSpace
Protagonist Therapeutics announced that management will host an investor conference call and webcast to provide a brief corporate update and discuss data from its ongoing Phase 2 clinical study evaluating rusfertide in polycythemia vera, which was selected as an oral presentation at the European Hematology Association 2021 Annual Congress.
   Protagonist wins FDA Breakthrough Therapy Designation for blood cancer therapy  2021/06/03 11:27:59 Seeking Alpha
   Protagonist Therapeutics Receives FDA Breakthrough Therapy Designation for Rusfertide in Polycythemia Vera  2021/06/03 00:00:00 BioSpace
Protagonist Therapeutics today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for its lead investigational new drug candidate, rusfertide, for the treatment of patients with polycythemia vera (PV)
   Protagonist, Janssen Win Breakthrough Therapy Designation for Oncology Candid...  2021/06/03 00:00:00 BioSpace
Shares of Protagonist Therapeutics climbed nearly 4% in premarket trading after the company announced its lead drug candidate rusfertide snagged Breakthrough Therapy Designation from the U.S. FDA.

calendar